# US 2025/0367187 A1 · Quinoline derivative used for treating small cell lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367187 A1
- Document ID: US20250367187A1
- Status: Published application
- Kind: A1
- Application number: 19/248,771
- Filed: 2025-06-25
- Published: 2025-12-04
- Earliest claimed: 2018-09-18
- Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Applicants: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Inventors: Shanchun WANG; Ding YU; Xunqiang WANG; Bangan PENG; Lu LIU; Jie DAI; Hang ZHOU; Yadong MIAO
- Web page: https://patentgrep.com/patent/US20250367187A1

## CPC

- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 33/243: Platinum; Compounds thereof
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to the field of medicine, and provided thereby is a quinoline derivative used for treating small cell lung cancer. The 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof as provided by the present application may be used for the treatment of small cell lung cancer, especially for patients suffering from refractory relapsed small cell lung cancer, which may significantly prolong the survival time thereof; in addition, the therapeutic effect on brain metastatic small cell lung cancer is also very significant.

## Claims

### Claim 21

A method for treating small cell lung cancer, comprising administering to a patient in need of treatment a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof,

### Claim 22 (depends on 21)

The method according to claim 21, wherein the small cell lung cancer is one that has failed with at least two chemotherapy regimens.

### Claim 23 (depends on 21, 22)

The method according to claim 21, wherein the small cell lung cancer is one that has failed with second-line and/or higher-line chemotherapy, The method according to claim 22, wherein the chemotherapy is one or more of

### Claim 24 (depends on 22)

The method according to claim 22, wherein the chemotherapy is one or more cisplatin, etoposide, carboplatin, nedaplatin, oxaliplatin, miriplatin, lobaplatin, irinotecan, topotecan, paclitaxel, docetaxel, temozolomide, vinorelbine, gemcitabine, cyclophosphamide, doxorubicin, vincristine, bendamustine, epirubicin, methotrexate and amrubicin.

### Claim 25 (depends on 21)

The method according to claim 21, wherein the pharmaceutically acceptable salt thereof is a salt formed by the compound of formula I and any of the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentane propionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, p-toluenesulfonic acid, 3-phenylpropionic acid, trimethylacetic acid, t-butylacetic acid, dodecyl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, and stearic acid.

### Claim 26 (depends on 21)

The method according to claim 21, wherein the compound of formula I or the pharmaceutically acceptable salt thereof is administered at a daily dose of 3 mg to 30 mg.

### Claim 27 (depends on 21)

The method according to claim 21, wherein the compound of formula 1 or the pharmaceutically acceptable salt thereof is administered in an intermittent regimen of treatment periods and interruption periods; wherein the ratio of the treatment period to the interruption period in days is 2:0.5-2:5.

### Claim 28 (depends on 21)

The method according to claim 21, wherein the small cell lung cancer is advanced small cell lung cancer or metastatic small cell lung cancer.

### Claim 29 (depends on 21)

The method according to claim 21, wherein the small cell lung cancer is refractory and relapsed small cell lung cancer or extensive-stage small cell lung cancer.

### Claim 30 (depends on 21)

The method according to claim 21, wherein the small cell lung cancer is one with brain metastasis.

### Claim 31 (depends on 21)

The method according to claim 21, wherein the small cell lung cancer is refractory and relapsed small cell lung cancer that has been previously treated with one or more of irinotecan, platinum, paclitaxel, and docetaxel.

### Claim 32 (depends on 21)

The method according to claim 21, wherein the pharmaceutically acceptable salt thereof is a hydrochloride salt or maleate salt.

### Claim 33 (depends on 21)

The method according to claim 21, wherein the pharmaceutically acceptable salt thereof is a dihydrochloride salt.

### Claim 34 (depends on 21)

The method according to claim 21, wherein the compound of formula I or the pharmaceutically acceptable salt thereof is administered in an intermittent regimen, wherein the intermittent regimen is one of the following cycles: 2-week treatment plus 2-week interruption, 2-week treatment plus 1-week interruption, and 5-day treatment plus 2-day interruption.

### Claim 35 (depends on 21)

The method according to claim 21, wherein the compound of formula I or the pharmaceutically acceptable salt thereof is administered for 2 weeks and interrupted for 1 week.

### Claim 36

A method for treating small cell lung cancer, comprising administering to a patient in need of treatment a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier,

### Claim 37 (depends on 36)

The method according to claim 36, wherein the small cell lung cancer is one that has failed with at least two chemotherapy regimens.

### Claim 38 (depends on 36)

The method according to claim 36, wherein the small cell lung cancer is one that has failed with second-line and/or higher-line chemotherapy, and/or is refractory and relapsed small cell lung cancer.

### Claim 39 (depends on 36)

A kit comprising (a) at least one unit dose of the pharmaceutical composition according to claim 36 and (b) instruction for treating small cell lung cancer in an intermittent regimen.
